Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Orchid Pharma Plunges 4%; BSE HEALTHCARE Index Up 0.4%
Thu, 27 Jun 16:5

Orchid Pharma Plunges 4%; BSE HEALTHCARE Index Up 0.4%Image source: Sefa Ozel/www.istockphoto.com

Orchid Pharma share price has plunged 4% and is presently trading at Rs 1,165.9.

Meanwhile, the BSE HEALTHCARE index is at 36,831.0 (up 0.4%).

Among the top losers in the BSE HEALTHCARE index today are POLY MEDICURE (down 3.6%) and HIKAL CHEMIC (down 3.1%).

CAPLIN POINT (up 7.3%) and SUVEN PHARMACEUTICALS (up 6.5%) are among the top gainers today.

Over the last one year, Orchid Pharma has moved up from Rs 498.4 to Rs 1,165.9, registering a gain of Rs 667.6 (up 134.0%).

On the other hand, the BSE HEALTHCARE index has moved up from 25,266.1 to 36,831.0, registering a gain of 45.8% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Cadila Healthcare (up 88.9%), Glenmark Pharma (up 88.9%) and GSK Pharma (up 87.4%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 79,245.0 (up 0.7%).

The top gainers among the BSE Sensex today are Ultratech Cement (up 5.3%) and NTPC (up 3.3%). The most traded stocks in the BSE Sensex are Tata Steel and Infosys.

In the meantime, NSE Nifty is at 24,036.1 (up 0.7%). Ultratech Cement and LTIMINDTREE are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 62,970.0 to 79,245.0, registering a gain of 16,275.0 points (up 25.8%).

Orchid Pharma Financial Update...

Orchid Pharma net profit fell 49.2% YoY to Rs 335 million for the quarter ended March 2024, compared to a profit of Rs 659 million a year ago. Net sales rose 3.4% to Rs 2,171 million during the period as against Rs 2,099 million in January-March 2023.

For the year ended March 2023, Orchid Pharma reported 197.1% increase in net profit to Rs 552 million compared to net loss of Rs 569 million during FY22. Revenue of the company grew 19.0% to Rs 6,659 million during FY23.

The current Price to earnings ratio of Orchid Pharma, based on rolling 12 month earnings, stands at 62.6.


Equitymaster requests your view! Post a comment on "Orchid Pharma Plunges 4%; BSE HEALTHCARE Index Up 0.4%". Click here!